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Abbreviations: 
 
A1AT = alpha-1-antitrypsin 
ACHD = adult congenital heart disease 
AF = atrial fibrillation 
AP = atriopulmonary 
ANZFR = Australia New Zealand Fontan Registry 
ARNIs = Combined angiotensin-receptor and neprilysin inhibitors  
AP = atriopulmonary Fontan 
AV = atrioventricular 
BDCPA = bidirectional cavopulmonary anastomosis 
BNP = brain natriuretic peptide 
CO = cardiac output 
CT = computed tomography 
CVP = central venous pressure 
EC = extracardiac Fontan 
EF = ejection Fraction 
GFR = glomerular filtration rate 
GI = gastrointestinal 
HF = heart failure 
HLHS = hypoplastic left heart syndrome 
IART = interatrial reentry tachycardia  
INR = international normalized ratio 
IVC = inferior vena cava 
VSD = ventricular septal defect 
LT = lateral tunnel Fontan 
MCS = mechanical circulatory support 
NOAC = novel oral anticoagulant 
NT-proBNP = N-terminal pro-brain natriuretic peptide 
OHT = orthotopic heart transplantation 
PA = pulmonary artery 
PDE5 = phosphodiesterase-5  
PLE = protein losing enteropathy 
PVR = pulmonary vascular resistance 
RA = right atrium 
SV = single ventricle 
SVR = systemic vascular resistance 
TA = Tricuspid atresia 
TCPC = total cavopulmonary connection 
TE = thromboembolic 
VKA = vitamin K antagonists 
WHO = World Health Organization 
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ABSTRACT 
In 1971, Fontan and Baudet described a surgical technique for successful palliation of patients 
with tricuspid atresia. Subsequently, this technique has been applied to treat most forms of 
functional single ventricles and has become the current standard of care for long-term palliation 
of all patients with single ventricle congenital heart disease.  Since 1971, the Fontan procedure 
has undergone several variations. These patients require lifelong management including a 
thorough knowledge of their anatomic substrate, hemodynamic status, management of rhythm 
and ventricular function along with multi organ evaluation. As these patients enter middle age, 
there is increasing awareness regarding the long-term complications and mortality. This review 
highlights the long-term outcomes of the Fontan procedure and management of late sequelae. 
 
Key Words: Adult congenital heart disease; Fontan  
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INTRODUCTION 
The Fontan procedure, devised by Fontan and Baudet was first performed in  France well over 
40 years ago [1].  Prior to the Fontan procedure, single ventricle (SV) patients rarely survived 
past early adulthood, and those that did were nearly universally cyanotic during their short lives.  
Theoretically, the Fontan operation separates the systemic and pulmonary venous returns to 
ameliorate the disadvantages of long-term hypoxemia, reduce thromboembolic (TE) events, 
preserve ventricular function, and prolong survival [2]. Candidates for the Fontan procedure 
must be carefully selected to give each procedure an optimal chance of succeeding. The ideal 
age for the Fontan operation is still debated despite advances in surgical techniques over the 
years.  
 
Over time, the Fontan procedure has continued to evolve, leading to improved early and 
intermediate prognoses. However, it remains a palliative procedure and limited in its ability to 
fully eliminate the problems associated with SV physiology. Surgical approaches to palliating SV 
physiology must focus on ameliorating the two major challenges of this parallel circuit of blood 
flow: (1) cyanosis induced by mixing of systemic deoxygenated and pulmonary oxygenated 
blood and (2) chronic volume overload assumed by the single functional ventricle, which leads 
to dilatation, hypertrophy, and failure without palliation [3]. As Fontan patients move to 
adulthood, there remains a steady attrition rate attributable to several known complications of 
the procedure, with the three most common modes of death being heart failure (HF) from 
ventricular dysfunction, thromboembolism and sudden death [3, 4]. There remain several other 
long-term complications including residual cyanosis, arrhythmias, protein losing enteropathy 
(PLE) and Fontan associated liver disease (FALD) [5-11] 
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STAGED PALLIATIVE SURGERY AND FONTAN VARIATIONS 
The Fontan operation was first used in 1968 for the repair of tricuspid atresia (TA) [1]. It 
included the insertion of an aortic or pulmonary homograft valve, at both the inflow and outflow 
of the right atrium (RA). In 1973, Kreutzer et al described the use of the pulmonary valve of a 
patient with TA to connect the RA to the pulmonary artery (PA) [12] Since then, several different 
types of Fontan modifications have been devised (FIGURE 1). Management strategies in the 
neonatal period are directed toward providing an adequate source of pulmonary blood flow 
either by creating an aorticopulmonary shunt (such as a Blalock-Taussig shunt) to augment 
pulmonary blood flow or by restricting excessive pulmonary blood flow to ensure adequate 
systemic blood flow.  An atrial septectomy or septostomy is done in most cases to ensure 
adequate pulmonary venous return to the systemic ventricle.  The first cavopulmonary 
connection is created in the first year of life via a bidirectional Glenn shunt. The Fontan 
circulation is completed by connection of the inferior vena cava (IVC) to the PA once growth of 
the pulmonary vasculature is appropriate, usually between 1 and 5 years of age. This staged 
surgical process serves to slowly acclimate the pulmonary vessels to the increased blood flow 
and the SV to decreased volume load in a stepwise fashion [3, 13] 
 
Years ago, the Fontan connection was made by anastomosing the RA to the PA, hoping to 
maintain some pump function in the pulmonary circuit using intrinsic contractility of the RA. This 
atriopulmonary (AP) Fontan has since been replaced by the total cavopulmonary connections 
(TCPC), which have less kinetic energy loss and more streamlined blood flow. TCPC include 
lateral tunnel (LT) and the extracardiac (EC) conduits, which have improved survival and 
hemodynamic superiority over the AP technique [3, 14]. The LT operation was introduced in the 
1980s and creates a path from the IVC to the PA using a prosthetic baffle sutured to a portion of 
the lateral wall of the RA [3, 15]. The EC conduit was introduced in the early 1990s and uses a 
tube of synthetic graft material to connect the IVC to the PA, bypassing the RA entirely and 
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minimizing risk of inducing atrial arrhythmias [3, 16]. Other less common types of Fontan such 
as Bjork-Kreutzer modification and intracardiac Fontan have also been performed less often but 
are beyond the scope of this paper.  
 
As TCPC operations have evolved over time, the AP Fontan has been abandoned due to 
excessive risk of arrhythmia, thrombosis, and early death.  Many patients with AP Fontans have 
been converted to TCPC Fontans, although the indications for doing so are controversial and 
surgical experience and survival rates vary from center to center (FIGURES 2, 3) [7]. Lateral 
tunnel Fontan is preferred at some centers given ability to implant an adequate sized conduit in 
younger children (< 24 months of age), and improved ability to fenestrate versus an extra-
cardiac Fontan [17].  However, at some centers, there has been a higher risk of sinus node 
dysfunction with LT Fontan versus EC Fontan.  EC Fontan is also easier to implement in 
patients with complex venous anatomy, such as heterotaxy.[17]  Since an EC conduit is unable 
to grow with the patient, in order to place an adequate-sized conduit that will last through 
adulthood, an EC conduit is typically placed at a later age than a LT [17].  
 
Frequently, in high-risk patients, a small fenestration is created between the conduit and the 
pulmonary atrium to allow a residual right-to-left shunt, thereby limiting caval pressure and 
congestion, but increasing the preload of the systemic ventricle and cardiac output (CO) at the 
expense of mild cyanosis. Fenestrations may be electively closed later via percutaneous 
catheter techniques. Low-risk Fontan patients can be managed surgically without a fenestration, 
thereby eliminating the future need for closure [3, 18]. 
 
LONG TERM SURVIVAL FOLLOWING FONTAN REPAIR 
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As surgical techniques and management of patients after the Fontan operation have improved 
over the last 40 years, there has been improvement in early and intermediate-term survival [2]. 
However overall survival remains inferior compared to the general population, with gradual 
attrition due to long term complications including TE complications, HF, arrhythmias and sudden 
death [4]. To date, the largest series analyzed are at Mayo Clinic (n=1052) [2] and the 
Australia/New Zealand Fontan registry (ANZFR) (n=1089) [19].  A recently published, large 
meta-analysis reviewing long-term outcomes of 5859 patients showed AP Fontans had much 
worse survival than EC or LT types, though ventricular morphology did not impact survival [20].  
 
The Mayo Clinic series reported 10-, 20-, and 30- year transplant-free survival rates of 74%, 
61%, and 43%, respectively [2].  These poor survival rates were likely due to a large proportion 
of the now-abandoned AP-type Fontans as well as poor survival due to the learning curve of the 
pioneering surgical era.  Downing et al. presented long-term follow up of 773 consecutive 
patients who underwent a first Fontan operation at a single institution during an 18-year period. 
The 20-year estimate for survival with intact Fontan circulation was 74%. Independent risk 
factors for death or loss of Fontan circulation were identified, but several of these characteristics 
conferred risk only in the early post-Fontan period. Late outcome was predicted only by 
presence of AV valve regurgitation pre-Fontan and length of post-Fontan ICU stay. Ventricular 
morphology and type of Fontan operation were not associated with early or late outcome [21]. 
More recently, Zannino and colleagues described long term outcomes for 683 adult survivors of 
the Fontan procedure in ANZFR. Fontan type was AP connection in 201 and TCPC in 482 
patients (249 LT and 233 EC). Survival for the entire cohort was 90% at 30 years and 80% at 40 
years of age, with survival at 30 years of age significantly worse for AP patients [22]. The 
authors concluded that the long-term survival is improving, but significant morbidity and 
mortality remain for these patients. Of note, most patients (65%) had systemic left ventricular 
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morphology. Additional risk factors for poor prognosis included male gender and moderate or 
severe AV valve regurgitation [22]. 
 
It should be highlighted that the management of hypoplastic left heart syndrome (HLHS) has 
changed substantially over the past four decades. In the 1970s, children with HLHS could only 
be provided with supportive care and died within the neonatal period. The advent of the 
Norwood procedure in the early 1980s has greatly improved prognosis, and the majority of 
patients now undergo a series of three surgical stages that support survival into early adulthood 
[23]. Despite these advancements, patients with HLHS have considerable long-term morbidity 
following Fontan operation, and early mortality remains common [4, 23]. Pundi et al. reported 
that only 40% of children with HLHS survived all three surgical stages and remained alive 10 
years after Fontan completion [2]. High systemic venous pressures, abnormal ventricular 
morphology, TE events, and recurrent arrhythmias create a tremendous burden of disease for 
these children as they reach adulthood. Exercise intolerance, HF, hepatic dysfunction, and 
disease processes more specific to patients with Fontan physiology such as PLE and plastic 
bronchitis are additional complications that can occur and further negatively impact the quality of 
life of patients with HLHS [24]. 
 
Survival for patients with HLHS who undergo Fontan completion ranges from 72% to 85% at 10 
years  [4, 25]. However, when accounting for all the surgeries required from infancy, the overall 
survival drops to only 50% to 70% at 10 years [25, 26].  Despite this, there are now a small 
number of HLHS survivors reaching adulthood [27]. In a recent multicenter study of 543 patients 
committed to Norwood surgery who could have reached 18 years of age by 2014, transplant-
free survival to adulthood was only 14%, with most mortality driven by the perioperative period 
of the Norwood procedure (41%).  As post-Norwood and interstage mortality continues to 
decrease, it is expected that the number of adult HLHS patients will continue to grow [28]. 
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LONG TERM COMPLICATIONS FOLLOWING FONTAN REPAIR 
Heart Failure 
HF after Fontan is very different from and much more complex than HF in acquired heart 
disease. Fontan failure is a clinical syndrome in which circulation can no longer meet the 
metabolic demands of the body. Patients with Fontan failure predominately suffer from systemic 
venous congestion. Four phenotypes of Fontan failure have been established with renal 
hypoperfusion as the common terminal pathway for all phenotypes [29].   
(I) Fontan failure with reduced ejection fraction (EF), which most closely resembles 
acquired systolic HF, is characterized by signs and symptoms of low EF and is the 
most common type of HF seen in the pediatric Fontan population.  
(II) Fontan failure with preserved EF, which is predominated by pulmonary venous 
congestion, elevation of Fontan pressures and hepatic congestion.  
(III) Fontan failure with normal pressures, which has a clinical presentation of right-sided 
HF including congestion, hepatomegaly, splenomegaly, ascites, varicose veins, and 
exercise intolerance despite normal EF and hemodynamics. Type III is caused by 
multi-organ system dysfunction, including portal venous outflow obstruction and 
adverse pulmonary vascular remodeling, making this group of patients particularly 
challenging to treat.  
(IV) Fontan failure with abnormal lymphatics, which can occur in the setting of normal 
ventricular function and normal hemodynamics; this presents with plastic bronchitis 
(more common in children) and PLE. 
 
A catheterization-based analysis by Hebson et al. described a phenotype of HF in the adult 
Fontan population that is hemodynamically distinct from traditional HF and is characterized by 
low systemic vascular resistance (SVR) and preserved CO [30].  In this study, the adult Fontan 
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population had higher central venous and pulmonary capillary wedge pressures than the 
pediatric Fontan cohort. However, SVR was lower in the adults and CO was preserved, even in 
patients with more severe symptoms. In a subanalysis comparing failing Fontan physiology in 
children versus adults with a systemic left ventricle, no significant difference in systolic 
ventricular function was seen.  However, adults with a systemic right ventricle had a significantly 
higher incidence of systolic ventricular dysfunction than children.  
 
Adult Fontan patients with Fontan failure more closely resemble the hemodynamic profile of 
portal hypertension (phenotypes II and III as above), with pathology secondary to time-related 
exposure to elevated post-sinusoidal Fontan pressure, leading to liver damage and eventually 
portal hypertensive-type circulatory derangement.  Of note, failing Fontan patients with 
preserved systolic function appear to do worse after orthotopic heart transplantation (OHT) than 
patients with decreased systolic function [31].  This paradoxical finding may be due to the 
limited ability to augment CO above a certain threshold from inability to augment stroke volume, 
regardless of EF, given lack of a venous capacitance chamber. [32-35]. Studies have 
demonstrated that skeletal muscle and ventilator pumps account almost entirely for the modest 
increase in stroke volume during exercise in patients with Fontan circulation.  Fontan patients 
have little hemodynamic reserve to overcome a decrease in venous return, and are essentially 
dependent on heart rate to augment CO [36].  
 
Since the phenotype of Fontan failure with preserved systolic function is distinct from that of the 
traditionally-accepted HF model, it brings into question whether treatment should resemble 
currently accepted HF therapy or rather the treatment for portal hypertension. Medications 
traditionally used in HF such as systemic vasodilators may not be well tolerated, and an 
approach more specifically tailored to the unique hemodynamics of the Failing Fontan may be 
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more beneficial [30]. It is also unclear how traditional diagnostics such as biomarkers and 
imaging aid in diagnostics and evaluation of the Failing Fontan patient.  
  
Brain natriuretic peptide (BNP), N-terminal pro-B natriuretic peptide (NT-proBNP), and serum 
sodium (hyponatremia) are biochemical parameters often monitored for HF exacerbations and 
have been shown to predict outcome in traditional HF. Use of biomarkers in Fontan patients 
continues to be investigated. Baggen et al. showed that elevated NT-proBNP levels were 
associated with increased risk of death or HF exacerbation [37]. BNP elevation has been shown 
to be a predictor of Fontan failure, mortality, and morbidity in adult patients in multiple studies 
[38, 39].  Hyponatremia has also been shown to be very common in adults with congenital heart 
disease (ACHD) and carries a high risk of mortality [40]  
 
In the Failing Fontan patient, cardiac and non-cardiac fibrosis are common and precede 
adverse outcomes in adulthood; therefore, biomarkers assessing fibrosis may be useful in 
assessing risk. These include galectin-3, a carbohydrate-binding protein, which is associated 
with a variety of biological effects including inflammation and fibrosis.  Opotowsky et al. showed 
that galactin-3 levels were elevated in Fontan patients compared with a control group, and 
correlated with worsened kidney function, advanced age, and higher risk of hospital admission 
or death.  Galectin-3 levels did not correlate with specific underlying ventricular morphology nor 
type of Fontan procedure [41].    
 
The paradigm of traditional HF treatment has two distinct scopes: symptomatic relief and 
mortality benefit. Symptomatic therapies focus both on traditional HF symptoms as well as 
unique Fontan-related problems such as plastic bronchitis,  protein losing enteropathy (PLE), 
and recurrent ascites. Given the lack of randomized controlled trials of HF therapy in Fontan 
patients, use of traditional HF medications is still widespread, with only very small trials and 
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expert opinion to guide decision-making.  In 2016, a systematic review of drug therapy trials in 
Fontan patients revealed only nine small trials with a total of 267 Fontan patients studied.  
Sildenafil was the drug most commonly examined [42]. Current evidence does not support the 
routine use of ACE inhibitors, β blockers, or pulmonary vasodilators in this population [43] and 
the lack of data has led to difficulty in treatment standardization.  
 
In a large Fontan registry, ACE inhibitors were used in about one third of Fontan patients and 
were almost twice as likely to be used in patients with HLHS than alternative morphologies.  
Only one third of patients given ACE inhibitor had an indication that would justify its use in a 
two-ventricle circulation [44].  In this study, indications for ACE inhibition included ventricular 
dysfunction (either systolic or diastolic), AV valve regurgitation, expectation that an ACE 
inhibitor would preserve ventricular function, history of prolonged effusions during initial Fontan 
surgery, and systemic hypertension [44].  Since failing Fontan physiology is often similar to 
hepatorenal syndrome, there is some concern that ACE inhibitors might be ineffective and 
potentially harmful in patients with type III Fontan Failure [45]. Additionally, ACE inhibitors have 
shown inability to improve exercise capacity or hemodynamics in pediatric and adolescent 
patients in at least one study [46].   
 
β-blockers have shown mixed results in both pediatric and adult Fontan populations.  It is well-
known that Fontan patients are dependent on heart rate to raise CO given the inability to 
significantly augment stroke volume with just one ventricle [36], thus lowering heart rate too 
much may have deleterious effects on CO.  On the other hand, a lower heart rate may improve 
diastolic filling, especially in patients with atrial arrhythmias, which might improve CO.  In a 
randomized controlled trial by Shaddy et al., β-blocker therapy did not improve outcomes for 
pediatric and adolescent Fontan patients with CHF [47]. Other studies have shown more 
promising results with β-blockers, including improvement of functional classification and 
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symptoms, [48-50] right ventricular remodeling, and improved exercise duration [51]. Combined 
angiotensin-receptor and neprilysin inhibitors (ARNIs), which have been extensively studied in 
acquired HF[52] could have benefit for Fontan patients with reduced EF and deserve further 
study.  Pulmonary vasodilators may increase cardiac filling in Fontan patients via lowering 
pulmonary vascular resistance (PVR), but have not consistently shown durable clinical 
outcomes.  Sildenafil has been shown to improve echocardiographic indices of myocardial 
performance [33].  Bosentan has been shown to have variable outcomes on exercise capacity 
and functional class in Fontan patients [53, 54].  In a small, randomized-controlled trial by 
Cedars et al., ambrisentan had a statistically significant, but clinically modest, improvement in 
exercise capacity [55]. One case report also demonstrated improvement in exercise capacity 
after treatment with macitentan  [56]. 
   
Progress with mechanical circulatory support (MCS) in SV patients has been limited, but 
remains increasingly important with growing populations of sick Fontan patients and limited 
supply of donor organs. The exact number of Fontan patients requiring transplant in the United 
States is elusive, as the United Network of Organ Sharing does not publish specific diagnoses, 
but rather lumps all congenital heart disease into a single group, including SV patients along 
with patients with two-ventricle physiology.  Most studies have focused on supporting patients 
with a failing systemic ventricle with limited reports of ventricular assist device support of the 
pulmonary circulation [57].  Available ventricular assist devices provide flows that are too high 
for the pulmonary vascular bed, and new devices are being developed to overcome this issue.  
Rodefeld et al. are performing preclinical testing on a novel Fontan-specific cavopulmonary 
assist device, which has a goal of providing a modest pressure boost to existing blood flow to 
effectively restore a more stable biventricular status [58] 
OHT in Fontan patients brings many distinct challenges and considerations.  The transplant 
surgery itself involves significant effort to take down the Fontan to reconstruct connections for 
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the transplanted heart, and all Fontan patients have had extensive prior surgery. The exact 
timing of OHT evaluation in Fontan patients remains uncertain.  Determining if enough decline 
has occurred to justify OHT, while at the same time planning for OHT early enough so a patient 
will survive and therefore benefit is an important but difficult process.  Criteria to help determine 
timing for transplant include a combination of declining functional status and changes on 
imaging, biomarkers, and cardiopulmonary exercise testing [59]. In the United States, only a 
very small minority (3.3%) of adult OHT occur in CHD patients [60]. Indications for OHT after 
Fontan include systemic ventricular failure refractory to medical therapy, chronic passive 
congestion, intractable ascites, and progressive cyanosis leading to functional decline. 
Currently, OHT wait-list mortality or delisting due to worsening clinical status is 
disproportionately common for ACHD patients listed as status 1A in the United States [61]. It is 
controversial if the current allocation system is appropriate for ACHD and whether it should be 
adapted given the unique aspects of this patient population [62].  Given the high incidence of 
FALD, some centers have started performing combined heart-liver transplants, although there 
overall is very limited experience with this technique; and very few centers have performed 
more than 10 combined OHT-liver transplants on Fontan patients [63].  
 
Thrombosis  
Despite changes in the surgical design of Fontan, and although the AP Fontan has largely been 
abandoned, thrombosis continues to be a major problem following the Fontan procedure [64]. 
The reported prevalence of thromboembolic (TE) events is as high as 33%, contributing to 
approximately 25% of mortalities via deep venous thrombosis, pulmonary embolism, or 
cerebrovascular accident [64-66]. Thrombosis risk factors include non-pulsatile pulmonary flow, 
low cardiac output, arrhythmias, type of Fontan connection, residual shunts or intentional 
fenestration, dilated atrium, ventricular dysfunction, hypoxia, liver disease, PLE, and underlying 
coagulation abnormalities [65-67]. In some small studies, Fontan patients have been found to 
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have decreased levels of anticoagulant proteins (proteins C and S) and an increase in 
prothrombotic factors (factor VIII and von Willebrand factor). [65].  
 
Most clinicians treating Fontan patients agree with routine use of pharmacologic prophylaxis 
against TE events, but there is no consensus on what specific medication(s) should be used 
[65, 67].  Some authors favoring antiplatelet medications (usually aspirin), while others favor 
vitamin K antagonists (VKA) such as warfarin. In a large meta-analysis on thromboprophylaxis 
in Fontan patients, aspirin was statistically noninferior to VKA with regard to TE events, but 
patients in neither group had many TE events [65]. A retrospective multicenter study (TACTIC) 
evaluating anticoagulation therapy for atrial arrhythmias (in a wide variety of CHD types, 
including Fontan patients) also showed no significant difference between the use of antiplatelet 
or VKA therapy in the prevention of TE events, though bleeding events were higher in the VKA 
group (p=0.039). Of note, patients with more complex congenital heart lesions were more likely 
to have a TE event (p<0.001), and risk scores used in general adult cardiology to predict TE 
events (CHADS2 and CHA2DS2-VASc scores) did not accurately predict TE events in Fontan 
patients [68]. Events in VKA patients often are caused by failure to maintain a therapeutic 
International Normalized Ratio (INR); and some studies have suggested that well-managed 
pharmacist-assisted protocols can help reduce overall event rates of both bleeding and 
thrombosis [69].  
 
Given the intrinsic limitations of VKA therapy, novel oral anticoagulant (NOAC) therapy to 
prevent TE events is increasingly being considered in Fontan patients, despite very limited data 
regarding safety or efficacy [70]. NOACs are often favored as they do not require blood draws 
for INR monitoring, have no dietary interactions, and may lead to better medication compliance 
and improved quality of life [71].  The NOTE registry has been actively recruiting patients to 
determine effectiveness and safety of NOACs in ACHD patients.  A recent publication from 
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NOTE showed only 8 minor events in the first 30 days after starting a NOAC for arrhythmia in 
99 patients.  Events included nonfatal bleeding and other minor side effects in patients who 
transitioned from VKA to NOAC therapy, and there were no reported adverse events in those 
who were started on a NOAC without prior anticoagulation [71]. Another study evaluating NOAC 
use in Fontan patients resulted in only one thrombotic event and no major bleeding, though this 
was a small (n=21), retrospective, single-center study  [72]. 
 
The use of anticoagulation in patients with the Fontan procedure to prevent TE events has been 
associated with fewer hospitalizations and a lower risk of death [67]. Being on either aspirin or 
VKA therapy is clearly superior to no such therapy for Fontan patients.  At this time, the agent(s) 
used is generally based on regional institutional preferences and further data is awaited [73].  
 
Arrhythmias 
Arrhythmias, particularly atrial tachyarrhythmias, are extremely common in the Fontan 
population.  Due to proximity of the surgical Fontan connections to the sinus node, iatrogenic 
sick sinus syndrome is quite common.  Catheter ablation as well as pacemaker placement are 
much more challenging in Fontan patients than in patients with two-ventricle circulations. 
 
In congenital heart disease populations, atrial fibrillation (AF) incidence increases with aging, 
higher complexity of ACHD, and increased numbers of surgical interventions (due to resulting 
surgical scar). Acquired cardiovascular comorbidities, such as hypertension, obesity, sleep 
apnea, and coronary disease, appear to increase the incidence and burden of AF; and as 
Fontan survivors are aging, these acquired cardiovascular conditions are becoming more 
prevalent. Atypical atrial flutter and incisional interatrial reentrant atrial tachycardia (IART) are 
exceptionally common due to direct injury and scarring of the right atrium from the initial 
surgery, as well as due to post-Fontan alterations of progressive right atrial dilation and 
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hypertrophy [74]. AP Fontan procedures may lead to right atrial gigantism, thus compressing the 
right upper pulmonary vein and leading to AF.  Approximately 50% of patients with right atrial–
right ventricular (Bjork) or AP Fontan procedures develop atrial tachycardia within 10 years of 
their palliative procedure. Improved surgical techniques have led to a diminishing burden of 
atrial arrhythmias, but they remain very common [75]. 
 
Patients with residual cyanosis after Fontan are also at increased risk for AF due to chronic 
subendocardial ischemia given limited oxygen reserves and high viscosity [76].  Generally, 
ACHD patients tolerate AF more poorly than the general population and have a higher risk of TE 
events and hemodynamically instability at rapid heart rates.  Also, Fontan patients tend to 
develop AF at a much younger age than the general population, and AF is more challenging to 
manage with medications or catheter-based and/or surgical ablation procedures. 
 
Amiodarone has been used for adults since the 1960s and is widely considered to be the most 
effective antiarrhythmic drug, including in the ACHD population. It should be administered with 
caution in the latter group because of its daunting long-term side-effect profile, which includes 
potential harm to the thyroid, lungs, liver, and eyes  [77]. Fontan patients with arrhythmias are 
more like to be refractory to single-drug antiarrhythmic therapy, have depressed myocardial 
function, and be intolerant of drugs with negative inotropic effects [78]. Patients with double inlet 
left ventricle who underwent surgical repair before the routine use of the Damus-Kaye-Stansel 
reconstruction have a pulmonary artery stump that is oversewn with a resultant pulsatile swirling 
of blood, creating a high-risk nidus for thrombus formation. This type of repair necessitates life-
long anticoagulation, even in the setting of normal sinus rhythm [79].   
 
Although the incidence of atrial tachycardia after Fontan surgery is high, access to the 
pulmonary venous atrium, a frequent site of arrhythmia origin, is often difficult and potentially 
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risky, as it requires a transbaffle puncture in a TCPC Fontan (unless there is a patent 
fenestration).  In AP Fontan patients, the right atrium remains connected to the great veins, but 
getting across the septum is very difficult due to the degree of atrial enlargement and 
hypertrophy as well as the lack of commercially available trans-septal catheters long enough to 
reach target areas.   
 
When traditional percutaneous access is difficult or impossible, other routes can be considered.  
Nehgme et al. descripted utilizing direct puncture of the chest wall (percutaneous transthoracic 
access) with fluoroscopic guidance to obtain access to the pulmonary venous atrium in six LT 
Fontan patients  [80].  Mapping and ablation catheters were placed in the pulmonary venous 
atrium, and additional electrophysiologic catheters were placed within the Fontan baffle and 
esophagus.  Complications included one pneumothorax and two hemothoraces requiring 
drainage.  Another new procedure that was recently described involves CT-guided transconduit 
puncture in patients with EC Fontan, in which the dilator tip is grasped with a snare catheter 
[81]. Subxiphoid and epicardial approaches may be used in patients without ACHD, however, 
they are generally not employed for patients with ACHD.   Both these approaches rely on the 
ability to access the pericardial sac, which in Fontan patients is likely to be immobile and 
scarred with thick, fibrous adhesions [82].  
 
Surgical ablation is considered the gold standard for invasive rhythm control in SV patients. 
Early surgeries involved conversion of AP Fontan to TCPC Fontan in conjunction with surgical 
ablation for AF [83]. Fontan conversion that did not include surgical ablation has been 
associated with a high incidence of postoperative atrial arrhythmias [84].The surgical approach 
has since progressed from isthmus ablation, to a modified right-sided maze procedure, and 
eventually to the MAZE-Cox III (right and left-sided maze) procedure for AF [85, 86].  
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With three-dimensional mapping and pace-mapping techniques, the focus of ventricular 
arrhythmias can be marked by an ablation catheter. This allows for the localization and surgical 
excision of the arrhythmogenic tissue, thereby substantially reducing the possibility for future 
ventricular arrhythmias and resultant ICD discharges [87]. SV patients scheduled for Fontan 
revision may be appropriate candidates for similar hybrid approaches that include surgical 
resection of arrhythmogenic atrial tissue.  
 
With advanced planning, patients undergoing open-thoracotomy procedures can have epicardial 
leads placed intraoperatively, potentially avoiding another open sternotomy or thoracotomy if 
they develop a future pacing indication.  Therefore, surgical ablation should always be 
discussed whenever an open heart surgical procedure is planned in these patients. Finally, 
elective surgical excision of thrombogenic structures such as the left atrial appendage and 
residual, ligated, blind-ended pulmonary artery stump should be performed if feasible and with 
low enough risk at the time of concomitant open heart cardiac surgical repairs. 
 
Residual Cyanosis  
Cyanosis late after Fontan is common.  Fontan patients may remain mildly hypoxemic, even 
after full repair and closure of atrial level shunts.  Cyanosis can significantly worsen over time. 
Desaturation is secondary to multiple causes including an intentionally placed surgical 
fenestration, persistent coronary sinus drainage into the right atrium, pulmonary arteriovenous 
malformations, aorticopulmonary collaterals, or venovenous collaterals [3]. The degree of 
cyanosis may not be readily apparent at rest and can be unmasked by exercise.  Persistently 
cyanotic Fontan patients without a known fenestration may benefit from interventional 
catheterization by an appropriately trained operator who can evaluate and treat these various 
causes of right-to-left shunts by deploying a variety of coils and devices (FIGURE 4). [70, 88]. 
Unfortunately, clinically significant venous collateral channels and other right-to-left shunts tend 
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to recur after coiling or device closure [89].  Closure of venovenous collaterals in some series 
has been found to be associated with a higher overall mortality rate [90]. If cyanosis cannot be 
corrected (or is accepted in a patient with intentional fenestration), appropriate preventative 
measures to avoid air embolism should be instituted such as the use of air filters with 
intravenous lines. Anticoagulation therapy is recommended for all patients with cyanosis or 
fenestration post-Fontan due to the risk of paradoxical systemic TE [70].  
 
Protein Losing Enteropathy  
PLE is a rare complication that can develop in patients following Fontan palliation, occurring in 
5-15% of patients [91, 92]. PLE may present as early as a few weeks after the Fontan 
operation, but on average presents 3-8 years after Fontan surgery [93, 94]. PLE is manifested 
by the severe loss of proteins, immunoglobulins and clotting factors via the gastrointestinal (GI) 
tract. A prevailing theory is that serum protein enters the lumen of the GI tract due to a loss of 
the intestinal barrier to protein permeability [95]. Typically, patients will have diarrhea due to 
excessive protein losses and subsequent bowel wall edema; however, not all patients present 
with diarrhea. Other symptoms may include abdominal cramping, ascites, electrolyte 
disturbances, peripheral edema, weight loss/gain, fatigue, and pleural or pericardial effusion 
[93]. Muscle tetany may occur secondary to hypocalcemia and thromboembolism is also a 
concern due to hypercoagulability.  PLE can result in significant morbidity and mortality for this 
patient population, with a 5-year survival after diagnosis of only 46-59%  [96].  
 
If PLE is suspected, diagnosis can be confirmed with testing of serum levels of albumin and 
protein, and testing for presence of elevated stool α-1-antitrypsin (A1AT). A1AT is a protein that 
is normally excreted in only small amounts into the stool, thus elevated levels are an indicator of 
protein leak into the intestinal mucosa. A 24-hour stool A1AT clearance study is more sensitive 
than random stool levels of A1AT [94].  Unfortunately, no single test can definitively confirm or 
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refute the diagnosis of PLE in the Fontan population. A proposed set of diagnostic criteria 
includes the presence of clinical manifestations of PLE, decreased serum albumin levels to <3.5 
g/dl, serum protein <6.0-6.3 g/L, and fecal A1AT clearance >27 ml/24hr without diarrhea and 
>56 ml/24h with diarrhea [97].  
 
There are several hypotheses about what leads to the development of PLE in the Fontan 
population. Systemic venous pressure is chronically elevated in the Fontan circuit, leading to 
chronic passive venous congestion of the liver and intestines, which results in an increase in 
tissue and lymphatic fluid generation [94, 95]. The intestinal lymphatics become engorged and 
proteins are “lost” into the intestinal lumen. Intravascular oncotic pressure is reduced and fluid 
leaks out of the vascular spaces and into the interstitium, which results in peripheral edema, 
ascites and effusions that are common in patients with PLE [96]. PLE presents when the 
patient’s ability to resynthesize lost protein is exceeded by the amount excreted in the intestine 
[94]. Chronically low CO in the Fontan circulation also results in poor perfusion of the GI 
mucosa, which results in chronic inflammation, and an increase in interferon-y, tumor necrosis 
factor-α, and serum albumin transmission across the intestinal mucosa. Elevated BNP levels 
can contribute to PLE by impeding lymph transport. Since not all patients with the Fontan 
circulation develop PLE, it has been hypothesized that individuals who develop PLE may have a 
congenitally abnormal lymphatic system [94].  
 
Treatment for PLE is targeted towards decreasing protein loss and reducing symptoms by 
decreasing CVP, improving cardiac function, reducing inflammation, and improving nutrition [96, 
98].  Identifying reversible hemodynamic abnormalities is an important step in treatment. 
Obstruction to systemic venous flow, which elevates venous pressures, should be corrected 
with balloon angioplasty and stenting [99]. Creating a Fontan fenestration (generally by 
catheterization) results in a Fontan pressure “pop-off,” which can lower Fontan pressure and 
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improve systemic cardiac output, although at the expense of reducing oxygen saturation.  
Fontan fenestration is rarely a long-term solution, however, given the high incidence of 
spontaneous fenestration closure, and thus it is generally considered to be a bridge to cardiac 
transplant or Fontan revision [100].  Atrial or ventricular pacing to increase heart rate may in 
some cases help improve symptoms via increasing CO [91].  
 
Pharmacological treatments include loop diuretics and aldosterone antagonists to decrease 
edema. Afterload reducing medications such as ACE inhibitors and angiotensin receptor 
blockers may improve cardiac output by reducing SVR. Pulmonary vasodilators such as 
phosphodiesterase-5 (PDE5) inhibitors may help reduce PVR and subsequently CVP. PDE5 
inhibitors have also been shown to improve mesenteric arterial blood flow. Corticosteroids can 
reduce inflammation; however long-term use leads to other well-known complications of long 
term steroid use. Oral budesonide is more enteric-specific with less systemic absorption, which 
limits systemic side effects; and therefore is often used for long term management of PLE [101]. 
Heparin has been shown to decrease inflammation (by inhibiting mast cell activity in the 
intestine), and also provides a barrier to larger molecules such as albumin [96]. Heparin can 
also reduce the occurrence of pulmonary and mesenteric micro-thrombi.  Octreotide mimics 
natural somatostatin and can decrease thoracic duct lymphatic flow [93]. 
 
Diet modification is also an important component of treatment. Malnutrition and failure to thrive 
are common sequelae of PLE.  As a result, attention to incorporating a high protein diet (>/= 2 
g/kg/d), high medium chain triglycerides, low sodium, and low fat (<25% calories) diet may also 
benefit patients [94].  
 
Recent innovations have led to a focus on lymphatic system interventions for treatment of PLE. 
Liver lymphangiography is a useful tool in identifying dilated liver lymphatic ducts and can 
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demonstrate leakage into the intestine [102-104].  The lymphangiography is performed in 
conjunction with endoscopy. Blue dye is injected into the lymphatic vessels, and leaks are 
identified via endoscopy. These vessels can then be embolized, and this has been shown to 
temporary normalize serum albumin blood levels and result in symptomatic improvement, 
though there are significant risks to the procedure and more studies are needed to assess long-
term outcomes [104].  
 
Fontan-Associated Liver Disease 
FALD is a common complication of the Fontan circulation, which has been recognized with 
increasing frequency in adolescents and adults. All types of Fontan connection, including AP 
Fontan and the newer TCPC Fontan, are at risk for FALD [105]. The spectrum ranges from just 
mild histologic changes, to abnormal liver function tests, and to fulminant liver failure [106]. The 
etiology of FALD is not entirely known, but is likely multifactorial, with physiological 
derangements, particularly elevation in CVP, contributing to liver pathology [8, 107]. Other likely 
contributing causes include chronic lack of tissue oxygenation, lack of pulsatility of pulmonary 
arterial flow, and other medical and surgical complications [107].  Risk factors for FALD include 
higher Fontan pressures, increasing age, longer duration of Fontan, underlying hepatitis B or C, 
alcohol use, and hepatotoxic drug use [8]. 
 
The best way to evaluate for FALD is uncertain, and there are no established predictors of 
which patients are at greatest risk for developing it.  Patients after Fontan with frank cirrhosis 
have reduced life expectancy, even after heart transplant.  It remains to be seen what effect on 
long-term survival milder forms of hepatic fibrosis have in Fontan patients [108].  
   
The lack of reliable tests to determine severity and progression of FALD is a significant clinical 
problem. Several clinical, imaging, and laboratory elements have been identified in an effort to 
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determine a useful scoring system to help risk-stratify these patients (such as the MELD and 
VAST scores) [109-112].  Basic serum liver function tests including aminotransferases, alkaline 
phosphatase, bilirubin, coagulation markers, and protein levels have generally not correlated 
with degree of liver disease [11]. Other evaluation for FALD includes liver imaging, cardiac MRI, 
liver biopsy, and transient liver elastography by ultrasound or MRI.  Given the concerns of high 
venous pressure being the culprit for hepatic fibrosis, many studies have compared 
hemodynamic evaluation with liver findings.  Noninvasive measurement of Fontan pressure, 
unfortunately, has been elusive; thus direct pressure measurement in the catheterization 
laboratory is generally considered when accurate hemodynamic assessment is needed.  
Several single-center studies have been done evaluating different modalities, but data sets are 
limited and generally do not include hemodynamic data, making it difficult to draw any 
conclusions. 
 
Symptoms of hepatic dysfunction in Fontan patients can be very subtle, and synthetic function is 
often preserved despite severe hepatic involvement.  Ascites is common, but esophageal 
varices are rarely found.  Primary portal hypertension is rare in Fontan patients, and fibrosis is 
instead generally due to high systemic venous pressures [95].  Chronic  CVP elevation (> 20 
mmHg) is known to greatly increase risk for hepatic fibrosis, but significant and possibly 
irreversible hepatic dysfunction may occur with chronic CVP in the mid-teens [95].   The 
chronicity of CVP elevation may be more important than the degree of CVP elevation.  Rychik et 
al. demonstrated an eight-fold higher degree of hepatic collagen deposition in Fontan patients 
compared to non-Fontan controls and duration of time after Fontan completion correlated best 
with degree of fibrosis [95].  
 
Abnormal liver histology is present in nearly all patients after Fontan surgery. These findings 
range from mild fibrosis to full cirrhotic changes. In a recent series of 74 consecutive young 
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Fontan patients (mean age 16 years) undergoing liver biopsies, all biopsies had at least some 
degree of liver fibrosis, with some demonstrating advanced cirrhosis [113]. Wu et al. performed 
a retrospective analysis of liver histopathology samples available in 68 adult and pediatric 
Fontan patients, including both autopsy and biopsy specimens.  Every specimen had 
centrilobular fibrosis, with 41.2% grading as severe.  Portal fibrosis was found in 82.3% of 
specimens (14.7% with cirrhosis) and centrilobular fibrosis grade was worse in patients with a 
dominant single ventricle compared to a combined right and left systemic ventricle [114].   
Despite the high incidence of abnormal histopathology, neither centrilobular fibrosis nor portal 
fibrosis grade correlated with transplant-free survival or overall survival. 
 
Although there is a high incidence of hepatic fibrosis in Fontan patients, liver biopsy findings 
have not correlated well with clinical outcomes.  Liver biopsy results can be misleading, as 
fibrosis is patchy, and it is easy to obtain a false negative or false positive sample[115].   
Standard pathologic grading systems may mischaracterize hepatic fibrosis patterns in Fontan 
patients, since the areas of fibrosis are different in Fontan patients than in non-Fontan patients 
with portal hypertension [95].   
 
Prevention of FALD is an important but elusive clinical goal. This can be attempted by 
optimization of anatomy and physiology, as well as prevention of liver injury both prior to and 
after Fontan. Additional preventive strategies include immunization against and treatment of 
viral hepatitis, as well as avoidance of hepatotoxins and obesity (steatohepatitis).  Moderation of 
alcohol intake should be considered, although the effects of alcohol on FALD are unknown [8]. 
 
Liver function biochemistries are often normal, even in the presence of significant liver fibrosis in 
Fontan patients.  Given the concerns about potentially severe risks and uncertain benefits of 
liver biopsy, other testing has been developed.  The MELD score (Model of End Stage Liver 
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Disease) has commonly been used to risk-stratify patients in the general population to allocate 
organs for liver transplantation [112] as well as to risk-stratify cirrhotic patients who need open-
heart surgery [116].  This score is a mathematical model including serum creatinine, sodium, 
bilirubin and INR, as well as a correction variable if the patient is on dialysis.  Scores range from 
6 to 40, with higher scores being associated with a higher risk of death due to severe liver 
disease.   
 
Many Fontan patients are managed on chronic vitamin K antagonists, as their INRs are 
elevated out of proportion of the degree of liver disease; thus the MELD-XI score (MELD 
excluding INR) may have better prognostic value. MELD-XI correlates with degree of hepatic 
fibrosis [111], as well as mortality and need for heart transplant in adult Fontan patients [110, 
117]. Laboratory data in these patients usually demonstrates only mild abnormalities, even 
when advanced cirrhosis is present [118], making assessment of liver dysfunction with tools 
such as the MELD score [119] of limited clinical value. Consequently, the search for a more 
meaningful measure of liver function in this population is critical and remains ongoing [11].  
 
Elder et al. evaluated a novel risk score to determine risk of portal hypertension after Fontan 
they termed the VAST score (varices, ascites, splenomegaly, and thrombocytopenia)[109].  The 
score includes one point for each of these features, and a score > 2 points was considered to 
be consistent with portal hypertension.  This score was then validated retrospectively against 73 
adult and pediatric Fontan patients using logistic regression.  Features of portal hypertension, 
as identified as a VAST score > 2 were found in 36% of the cohort; and VAST score > 2 after 
adjusting for other variables resulted in a 9-fold increased risk of adverse events. 
 
Given the increasing morbidity associated with liver disease, identifying it early and with less 
invasive assessment has become paramount. Imaging has been shown to accurately identify 
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structural liver disease, but unfortunately not the degree or severity [3, 120]. Abdominal 
ultrasound with Doppler evaluation should be performed at baseline with consideration for 
elastography. Transient elastography by ultrasound or MRI has been evaluated by several 
groups as a manner for assessing hepatic stiffness. Its role, however, remains limited by 
difficulty in distinguishing edema from fibrosis [121]. Cardiac MRI routinely includes the liver in 
its field of view, and thus serial changes of liver can be evaluated as part of routine follow-up 
MRI.  In a recent study, Lewis et al measured IVC, right hepatic vein size, and spleen diameter 
in Fontan patients who had undergone serial cardiac MRI.  Over a mean time of 5.1 years, a 
significant increase in hepatic dimensions, right hepatic vein diameter, and mean spleen 
diameter was seen [105]. In 55% of patients, increasing hepatic congestion was found between 
studies.  Progressive hepatic congestion correlated with reduced SV EF < 50%, degree of 
ventricular dilation, and a higher MELD-XI score.  No association was between biochemical 
abnormalities and change in anatomic variables. Interestingly, only right hepatic vein diameter 
correlated with time from Fontan completion[105].   
 
Arguably the most devastating liver-related complication after Fontan palliation is the 
development of hepatocellular carcinoma (HCC) [122].  Precise incidence late after Fontan 
palliation is unknown.  A recent nationwide study of all 2700 Fontan procedures in Japan 
demonstrated a prevalence of 1.15% [122]. Treatment for HCC can include resection, 
chemoembolization, or in advanced cases, liver transplant, which may need to be combined 
heart-liver transplant.  Given advanced tumor burden at diagnosis in many cases, palliative care 
is often considered. Outcomes and risk factors for HCC are also unknown in the Fontan 
population.   Diagnosis of HCC can be made by combining imaging, alpha fetoprotein levels, 
and biopsy [123, 124].  Most reported cases of HCC have involved biopsy, although biopsy is 
unnecessary in cases with exceedingly high AFP levels.  In some cases, nodules that satisfy 
classic criteria for HCC have been found to be benign on biopsy in Fontan patients [125].  
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Testing serum alpha-fetoprotein and performing liver imaging every six months should be 
considered in patients with established FALD due to the increased risk for hepatocellular 
carcinoma [8] . 
 
There are no current medical therapies recommended for routine treatment of hepatic fibrosis in 
the Fontan population. The renin-angiotensin-aldosterone system is recognized as an important 
regulator of liver fibrosis, and there is evidence supporting anti-inflammatory and anti-fibrogenic 
effects of ACE inhibitors and angiotensin receptor blockers in the general population with liver 
disease [126]. However, no similar studies have been performed in FALD.  Caution with the use 
of these agents in the FALD  must be taken, as they may precipitate hepatorenal syndrome [11]. 
Management of severe FALD (patients with cirrhosis or stage III/IV fibrosis) is based upon 
optimization of the Fontan circulation and hepatology consultation.  Supportive care, such as 
serial paracenteses, can relieve symptoms.  In some cases, heart-only transplant may retard 
worsening of the liver disease; in more advanced cases combined heart-liver transplant may be 
necessary [8]. 
 
Chronic Venous Insufficiency 
Chronic venous insufficiency is common in the Fontan population.  Patients with venous 
insufficiency present with lower extremity edema, venous varicosities, skin changes, and 
venous ulcers. Valente et al. evaluated the risk of chronic venous insufficiency in a multicenter 
study of 159 adult Fontan survivors and showed that chronic venous insufficiency was much 
more common than in healthy controls (60% versus 32%), as was severe venous insufficiency 
(22% versus 0%).  Risk factors for severe chronic venous insufficiency included recurrent groin 
access for heart catheterization, itching of lower extremities, and a history of deep venous 
thrombosis [127].   
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Renal Disease 
Patients after Fontan are at risk of kidney injury and often have lower glomerular filtration rate 
(GFR) than healthy controls. This may reflect end-organ dysfunction caused by low CO and 
chronic venous congestion [128]. Younger age at initial Fontan, higher preoperative saturation, 
and higher preoperative blood pressure independently correlated with higher GFR at latest 
follow-up. Higher preoperative serum creatinine levels identified patients at highest risk for long-
term dysfunction [129].  Opotowsky et al. showed that traditional means of evaluating GFR 
using creatinine overestimates true GFR and that either cystatin C or urinary biomarkers may be 
a better reflection of true GFR [130].  
 
Plastic Bronchitis 
Plastic bronchitis is a rare condition after Fontan palliation in which mucofibrinous bronchial 
casts develop and result in marked airway obstruction. Patients often expectorate large casts or 
require urgent removal by bronchoscopy, and life-threatening events may occur in up to 40% of 
affected patients [131]. Plastic bronchitis occurs in 3-4% of Fontan patients [132] and is 
associated with similar risk factors as PLE [133]. Initial management of these patients is similar 
to that of PLE, including optimization of Fontan hemodynamics and ensuring there is no 
alternate reversible cause of elevated CVP. Proposed treatment options include inhaled or 
systemic steroids, aerosolized  mucolytics, and aerosolized fibrinolytics such as tissue 
plasminogen activator. Bronchoscopy is often needed for acute airway rescue [134].  
Intervention on abnormal lymphatics has resulted in clinical improvement in isolated patients 
with Fontan-related plastic bronchitis [135]. OHT can be effective as a long-term option for 
treating plastic bronchitis [136], although plastic bronchitis has occurred after OHT [137], and 
plastic bronchitis is a risk-factor for short-term mortality following OHT [138]. 
 
Lung Disease  
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Patients with Fontan often have a restrictive pattern on pulmonary function testing associated 
with reduced exercise capacity [139], and this is likely related to multiple prior sternotomies and 
chest wall deformities such as scoliosis that are very common, particularly following prior 
thoracotomy [140, 141]. Pulmonary function testing demonstrates reduced forced vital capacity, 
breathing reserve, and diffusing capacity; and cardiopulmonary exercise testing shows reduced 
functional capacity [140].  
 
Pregnancy in the Fontan Patient 
Patients with prior Fontan procedure who are contemplating pregnancy should undergo 
preconception assessment and counseling by an ACHD specialist, including a comprehensive 
cardiovascular evaluation to identify residual issues following Fontan operation that may 
adversely affect pregnancy outcome [142]. Women after Fontan are generally fertile, unless 
they are severely cyanotic.  Pregnancy is often well-tolerated in patients with good 
hemodynamics, reasonably normal oxygen saturation, no atrial arrhythmias, and no history of 
TE events, but there is still an elevated risk of adverse outcomes compared to healthy controls 
[142]. Women who have already had significant post-Fontan events or who are likely to be at 
high risk for such events should be discouraged from attempting pregnancy and should be 
offered safe and effective forms of contraception.  Fontan physiology is a thrombogenic state, 
thus high-estrogen containing medications are not favored [70]; and instead other forms of 
contraception should be considered such as intrauterine devices or intramuscular depot 
progesterone injections.  
 
The largest study to date evaluating pregnancy outcomes after Fontan is now over 20 years old 
[143] and thus included mostly AP Fontans. This data therefore needs to be interpreted with 
caution, given that AP Fontans have a much higher overall mortality rate than TCPC [2].  This 
survey-based study evaluated 116 female patients at several United States centers and 
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reported on 33 pregnancies in 14 women.  There were 15 (45%) live births, 13 spontaneous 
abortions, and 5 elective abortions.  There were no maternal complications reported during 
labor, delivery, or immediate postpartum period [143].  Sporadic cases of women with Fontan 
palliation having multiple pregnancies and healthy children have also been reported [144, 145] . 
 
Classification schemes have been devised to assess maternal cardiac risk.  The World Health 
Organization (WHO) classification system considers patients after Fontan to be in WHO 
Pregnancy Risk Category III, the second-highest risk category [146]. Genetic counseling should 
also be offered, ideally before conception [147]. A monitoring period of 24 hours (including 
telemetry) with close attention to signs of volume overload or arrhythmia prior to conception also 
seems reasonable [142]. Premature delivery may be necessary to alleviate maternal symptoms 
of volume overload or atrial arrhythmia.  The most common maternal complications reported 
during pregnancy in Fontan patients are atrial arrhythmias (especially in those women with atrial 
arrhythmias prior to pregnancy), TE events, and HF [142, 143].  
 
It is currently uncertain whether and what type of anticoagulation should be used during 
pregnancy. In general, low-molecular weight heparin is advised for women with a history of a TE 
event and/or atrial arrhythmia.  Vitamin K antagonists are teratogenic, although they can be 
used during the second and most of the third trimester of pregnancy with plans to switch to 
either intravenous heparin infusion or low-molecular weight heparin prior to delivery.  In the 
absence of prior problems most women are treated with just low-dose aspirin, as this had not 
demonstrated any increase in maternal bleeding events or fetal defects [142].  
 
Regular cardiology follow-up visits during pregnancy, more frequently if the patient becomes 
symptomatic, are recommended.  An interdisciplinary conversation between cardiology, high 
risk obstetrics, and other clinical staff should be undertaken to determine a detailed delivery 
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plan, with plans determined by the start of the third trimester, in the event of a preterm delivery. 
If the patient becomes symptomatic after the 38th week, labor should be induced, and may need 
to be induced earlier than that depending on maternal health.  There is no clear cardiac 
indication for Caesarean section in Fontan patients, but it may be necessary for obstetric 
reasons [142].  
 
SUMMARY 
Despite careful long-term follow-up, there remains continued late attrition of Fontan patients 
from long-term complications. As surgical techniques for the Fontan operation have improved, 
overall survival and quality of life have also improved, though Fontan patients remain vulnerable 
to many cardiac and non-cardiac complications.  As this population continues to age, other 
unexpected comorbidities will likely continue to arise. Management of these patients includes a 
detailed assessment to treat any correctable lesions, either surgically or with percutaneous 
techniques. The expert clinician needs to be aware of all potential complications and how to 
manage them.  Management of heart failure and arrhythmias and screening for liver disease are 
paramount.  PLE and plastic bronchitis are also severe, but fortunately rare, complications that 
require very specialized care and often consideration for transplantation.   
 
Newer testing modalities, such as invasive ambulatory hemodynamic monitoring [148] and 
newer therapeutics, such as lymphatic interventions, [102, 135] negative pressure ventilation, 
[149] and emerging blood pump technologies, [58, 150] are also being examined. The role of 
heart transplant or combined heart-liver transplantation remains controversial. Long-term 
outcomes for adult patients with Fontan palliation are continually improving, but much work 
remains to be done to further improve survival and quality of life for this complex cohort of 
patients.  
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Figure Legend 
 
Figure 1:  
Types of Fontan connection: A) atriopulmonary Fontan, with anastomosis of right atrial 
appendage directly to pulmonary artery; B) lateral caval Fontan, with a patch separating the 
venous inflow of the right atrium from the right atrial body, and anastomosis of superior vena 
cava to pulmonary artery; C) extracardiac Fontan, with a prosthetic tube conveying blood 
completely outside the body of the right atrium to the cavopulmonary anastomosis. 
Figure 2: 
Three-dimensional CT scan reconstruction of an atriopulmonary Fontan connection in a 30 year 
old woman scheduled for Fontan conversion to extracardiac Fontan.  RA = right atrium; RAA = 
right atrial appendage; Ao = aorta; PA = pulmonary artery 
 Figure 3: 
Angiogram in a 25 year old woman before and after Fontan conversion from AP Fontan to 
extracardiac Fontan.  (A) Prior to Fontan conversion showing massive dilated right atrium.  (B) 
Injection into IVC after Fontan conversion showing extracardiac tube connecting IVC directly to  
PA.  RA = right atrium; IVC = inferior vena cava; EC = extracardiac conduit; PA = pulmonary 
artery 
Figure 4: 
(A) Angiogram of a 28 year old lateral tunnel Fontan patient with exercise-induced cyanosis due 
to formation of a decompressing venovenous collateral.  SVC = superior vena cava; PA = 
pulmonary artery.  Red arrow showing location of venovenous collateral from innominate vein 
draining to pulmonary veins.  (B) Arrow demonstrating site of successful coil embolization of 
collateral. 
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